Carlsbad-based Banyan Biomarkers Inc. announced it has received $6 million in Series A funding from private investors to develop a diagnostic test for traumatic brain injury.
The company is currently conducting a 2,000-patient clinical trial funded with a $26.3 million contract from the U.S. Department of Defense.
The company is developing a simple blood test that can help physicians quickly detect brain trauma, and improve the medical management of head injury patients, it said in a release.
“We are extremely pleased to have such a group of highly experienced investors who will help us grow the company to the next level,” Jackson Streeter, CEO of Banyan Biomarkers, said in a statement. “Our groundbreaking research is poised to bring the first-ever diagnostic blood test for traumatic brain injury to the patient.”
He said the test will provide critical objective information to assist physicians in diagnosing and treating such injuries.
The Business Journal is the premier business publication in San Diego. Every day online and each Monday in print, the Business Journal reports on how local business operate and why businesses leaders make the decisions they do. Every story is a dose of insight into how to run a better, more efficient, more profitable business.
